A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-1
- Sponsors Eli Lilly
- 17 May 2018 Planned End Date changed from 19 Dec 2019 to 19 Mar 2020.
- 01 May 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 New trial record